RADARR
| Patologia: | Carcinoma ovarico |
| Area Tematica: | Oncologia |
| Data di Inizio Progetto: | 2026 |
| Data di Fine Progetto: | 2028 |
| Finanziamento: | € 451.100,00 |
| Partenariato | Istituto di Ricerche Farmacologiche Mario Negri IRCCS Istituto Europeo di Oncologia |
Ovarian carcinoma is an aggressive disease. PARP inhibitors improved patients’ outcomes, but resistant cases pose a clinical challenge. We will study the protein RAD51 to predict and treat resistant tumors. We will use clinical samples and laboratory models to test new drugs targeting RAD51 and explore how the immune system affects treatment, aiming to find better therapies for resistant patients.